HTGM.Q Stock Overview
HTG Molecular Diagnostics, Inc. a life sciences company, focuses on the precision medicine.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
HTG Molecular Diagnostics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0015 |
| 52 Week High | US$3.26 |
| 52 Week Low | US$0.0013 |
| Beta | 2.98 |
| 1 Month Change | -40.00% |
| 3 Month Change | 15.38% |
| 1 Year Change | -99.95% |
| 3 Year Change | -100.00% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
HTG Molecular Q2 GAAP loss per share widens, revenue down
Aug 11HTG Molecular Diagnostics amends senior loan facility
Jul 18Is HTG Molecular Diagnostics (NASDAQ:HTGM) Using Debt In A Risky Way?
Dec 10
Is HTG Molecular Diagnostics (NASDAQ:HTGM) Weighed On By Its Debt Load?
Aug 27HTG Molecular completes product design lock for planned transcriptome panel
Jun 14These Analysts Think HTG Molecular Diagnostics, Inc.'s (NASDAQ:HTGM) Sales Are Under Threat
Mar 26What Type Of Returns Would HTG Molecular Diagnostics'(NASDAQ:HTGM) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?
Jan 20
HTG shares surge after upbeat 2020 revenue forecast
Jan 05HTG Molecular Diagnostics announced 1:15 reverse stock split
Nov 23HTG Molecular Diagnostics (HTGM) Investor Presentation - Slideshow
Nov 18Shareholder Returns
| HTGM.Q | US Healthcare Services | US Market | |
|---|---|---|---|
| 7D | 0% | -6.1% | -3.7% |
| 1Y | -100.0% | -11.9% | 20.2% |
Return vs Industry: HTGM.Q underperformed the US Healthcare Services industry which returned -11.5% over the past year.
Return vs Market: HTGM.Q underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| HTGM.Q volatility | |
|---|---|
| HTGM.Q Average Weekly Movement | 282.0% |
| Healthcare Services Industry Average Movement | 9.9% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: HTGM.Q's share price has been volatile over the past 3 months.
Volatility Over Time: HTGM.Q's weekly volatility has decreased from 4116% to 282% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 54 | John Lubniewski | www.htgmolecular.com |
HTG Molecular Diagnostics, Inc. a life sciences company, focuses on the precision medicine. The company offers instruments; consumables; and software that automate sample processing and profiles various molecular targets. Its marketed molecular profiling panels include HTG Transcriptome Panel; HTG EdgeSeq precision immuno-oncology panel; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay EU; HTG EdgeSeq Oncology Biomarker Panel; HTG immune response panel; and HTG mouse mRNA tumor response panel.
HTG Molecular Diagnostics, Inc. Fundamentals Summary
| HTGM.Q fundamental statistics | |
|---|---|
| Market cap | US$3.32k |
| Earnings (TTM) | -US$20.15m |
| Revenue (TTM) | US$6.21m |
0.0x
P/S Ratio0.0x
P/E RatioIs HTGM.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HTGM.Q income statement (TTM) | |
|---|---|
| Revenue | US$6.21m |
| Cost of Revenue | US$11.13m |
| Gross Profit | -US$4.92m |
| Other Expenses | US$15.23m |
| Earnings | -US$20.15m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -9.10 |
| Gross Margin | -79.14% |
| Net Profit Margin | -324.28% |
| Debt/Equity Ratio | 1,452.4% |
How did HTGM.Q perform over the long term?
See historical performance and comparison